  |
||||||||
|
||||||||
| |||||||||||
Supplement to: Keller MB et al. A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. N Engl J Med 2000;342(20):1462-70.
Editor's note: Our policy requires authors of Original Articles to disclose all financial ties with companies that make the products under study or competing products. In this case, the large number of authors and their varied and extensive financial associations with relevant companies made a detailed listing in the print version of the article impractical. Details are included below and are also available (as document no. 05552) from the National Auxiliary Publications Service, c/o Microfiche Publications, 248 Hempstead Tpke., West Hempstead, NY 11552.
Dr. Keller has served as a consultant to or received honorariums from Pfizer, Bristol-Myers Squibb, Forest Laboratories/Parke-Davis, Wyeth–Ayerst, Merck, Janssen, Eli Lilly, Organon, and Pharmacia–Upjohn. He has received research grants from Wyeth–Ayerst, SmithKline Beecham, Upjohn, Pfizer, Bristol-Myers Squibb, Merck, Forest Laboratories, Zeneca, and Organon. He has served on the advisory board of Wyeth–Ayerst, Pfizer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories/Parke-Davis, Organon, SmithKline Beecham, Merck, Janssen, Mitsubishi Pharmaceuticals, Zeneca, Scirex, and Otsuka.
Dr. Klein has served as a consultant to Bristol-Myers Squibb.
Dr. Dunner has served as a consultant to Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, and Eli Lilly. He has received research grants from Bristol-Myers Squibb, Pfizer, Pharmacia–Upjohn, SmithKline Beecham, Forest Laboratories, Glaxo Wellcome, and Wyeth–Ayerst. He has received speaker's honorariums from Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, Eli Lilly, Organon, and Wyeth–Ayerst.
Dr. Gelenberg has received grants and research support from Bristol-Myers Squibb, Organon, Pfizer, Lilly Research Laboratories, Janssen, Merck Sharp & Dohme, SmithKline Beecham, Wyeth–Ayerst, Hoechst Marion Roussel, and Forest Laboratories. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Pfizer, SmithKline Beecham, Janssen, Lilly, Forest Laboratories, and Parke-Davis. He is a stockholder or has other ownership interest in Pfizer, Warner-Lambert, and Eli Lilly. He has served as a consultant to Eli Lilly, Scios, Forest Laboratories, Parke-Davis, Pfizer, Janus Pharmaceuticals, Best Practice, and Bristol-Myers Squibb.
Dr. Markowitz has received speaker's honorariums from Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, and Pfizer.
Dr. Nemeroff has been a consultant to or received honorariums from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi, Neurocrine Biosciences, Organon, Otsuka, Pfizer, Pharmacia–Upjohn, Sanofi, SmithKline Beecham, Solvay, and Wyeth–Ayerst. He has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Organon, Pfizer, Pharmacia–Upjohn, SmithKline Beecham, Solvay, and Wyeth–Ayerst.
Dr. Russell has been a consultant to or received honorariums from Abbott, Bristol-Myers Squibb, Janssen, Eli Lilly, Pfizer, and Quintiles. He has received research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Parke-Davis, Pharmacia–Upjohn, Pfizer, SmithKline Beecham, Wyeth–Ayerst, Shire, and Quintiles.
Dr. Thase has served as a consultant to Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome/Cerenex Pharmaceuticals, Merck, Organon, Pfizer, Pharmacia–Upjohn, and Wyeth–Ayerst. He has received grant and research support from Bristol-Myers Squibb, Lipha Pharmaceuticals, Merck, Organon, Pharmacia–Upjohn, and Wyeth–Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, Glaxo Wellcome/Cerenex Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia–Upjohn, SmithKline Beecham, Solvay, and Wyeth–Ayerst.
Dr. Trivedi has received research grants from Abbott, Akzo (Organon), Bayer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Janssen, Johnson & Johnson, MeadJohnson, Parke-Davis, Pfizer, Pharmacia–Upjohn, Solvay, and Wyeth–Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Forest Laboratories, Pharmacia–Upjohn, Solvay, and Wyeth–Ayerst.
Dr. Zajecka has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, Organon, Otsuka America, Parke-Davis, Pfizer, Pharmacia–Upjohn, and Sanofi Research. He has served as a consultant to or has served on the advisory board of Abbott, Bristol-Myers Squibb, and Eli Lilly. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, SmithKline Beecham, Upjohn, and Wyeth–Ayerst.
Dr. Blalock has served as a consultant to Bristol-Myers Squibb.
Dr. DeBattista has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Parke-Davis, Pfizer, Scios, SmithKline Beecham, Wyeth–Ayerst, and Organon. He has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Pfizer, the National Alliance for Research on Schizophrenia and Depression, Pharmacia–Upjohn, PharmaPrint/ABA, SmithKline Beecham, and Wyeth–Ayerst. He has served as a consultant to Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, and PharmaPrint.
Dr. Fawcett has received grants and research support from Abbott, Bristol-Myers Squibb, Glaxo, Eli Lilly, Organon, Pfizer, SmithKline Beecham, Wyeth–Ayerst, and Zeneca. He has served as a consultant to Abbott, Bristol-Myers Squibb, Eli Lilly, EM Industries, Forest Laboratories, Glaxo Wellcome, Pfizer, Pharmacia–Upjohn, and SmithKline Beecham. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, Pharmacia–Upjohn, SmithKline Beecham, and Wyeth–Ayerst.
Dr. Hirschfeld has received grants and research support from Abbott, Bristol-Myers Squibb, Organon, and Pfizer. He has served as a consultant to or on the advisory board of Abbott, Bristol-Myers Squibb, Glaxo Wellcome, Forest Laboratories, Eli Lilly, Pfizer, SmithKline Beecham, Janssen, Organon, Parke-Davis, and Pharmacia–Upjohn.
Dr. Kocsis has had research contracts with Bristol-Myers Squibb, Pfizer, Forest Laboratories, Eli Lilly, and Wyeth–Ayerst. He has received speaker's honorariums from Bristol-Myers Squibb, Forest Laboratories, and Eli Lilly. He owns stock in Pfizer and Forest Laboratories.
Dr. Kornstein has received research grants from Bristol-Myers Squibb, Pfizer, Eli Lilly, Glaxo Wellcome, Forest Laboratories, Mitsubishi Pharmaceuticals, and Biovail. She has served as a consultant to Bristol-Myers Squibb, Pfizer, Eli Lilly, and Pharmacia–Upjohn. She has received honorariums from Bristol-Myers Squibb, Pfizer, and Glaxo Wellcome.
Dr. Ninan has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Pharmacia–Upjohn, SmithKline Beecham, and Solvay. He has served as a consultant to Pfizer, TAPPharma, and Wyeth–Ayerst. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Parke-Davis, Pfizer, Pharmacia–Upjohn, SmithKline Beecham, Solvay, Janssen, and Wyeth–Ayerst.
Dr. Rothbaum has served as a consultant to Bristol-Myers Squibb and Pfizer. She has been a member of the advisory board of and a speakers' bureau sponsored by Pfizer.
Dr. Rush has received grants and research support from Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Novartis, Organon, Pfizer, Pharmacia–Upjohn, SmithKline Beecham, Wyeth–Ayerst, and Zeneca. He has served as a consultant to Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Merck, Organon, Pfizer, Pharmacia–Upjohn, and Wyeth–Ayerst. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Organon, Pfizer, Pharmacia–Upjohn, and Wyeth–Ayerst.
Dr. Schatzberg has served as a consultant to or received honorariums from Abbott, Bristol-Myers Squibb, Corcept Therapeutics, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia–Upjohn, Sanofi, Scirex, SmithKline Beecham, Solvay, and Wyeth–Ayerst. He has received research support from Bristol-Myers Squibb, Pfizer, and SmithKline Beecham. He has equity ownership in Corcept, Merck, Pfizer, and Scirex.
| |||||||||||
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
